Calida Therapeutics, a Paris, France based preclinical stage biotechnology company specialized in thrombo-inflammatory disorders, raised €2M in seed funding.
AdBio partners made the investment. In conjunction with the financing, Alain Huriez, chairman and managing partner at AdBio partners, will join Calida’s board of directors, alongside Clément Bertholet, operating partner at AdBio partners and CEO of Calida, and Dr. Daniel Simon.
The company intends to use the funds to conduct additional in vivo proofs of concept and select a lead candidate.
Co-founded in December 2022 by Dr. Daniel Simon, MD, PhD, Dr. Edward Plow, PhD, and Dr. Yunmei Wang, PhD, together with the venture capital funds BioMotiv and AdBio partners. Calida aims to develop monoclonal antibodies to treat and prevent thrombo-inflammatory disorders. Based on more than 20 years of research conducted in Cleveland (Ohio, USA) by leading researchers from the academic and medical ecosystem, Calida aims to become a leader in the new field of thrombo-inflammatory disorders. These occur in a broad range of indications, from cardiovascular diseases to the complications of autoimmune diseases. Its novel approach aims to disrupt the molecular link between thrombosis and inflammation by preventing the crosstalk between platelets and myeloid cells, thus abolishing the chain reaction of these two phenomena which can lead to tissue damage and life-threatening events.
FinSMEs
06/04/2023